

INTERNATIONAL HEALTHWAY CORPORATION LIMITED

Registration No.: 201304341E

(Incorporated in the Republic of Singapore)

(In receivership over charged shares in certain subsidiaries)



CLARIFICATION ANNOUNCEMENT ON THE NEWS ARTICLES PUBLISHED BY REUTERS AND LIANHE ZAOBAO

The Board of Directors (the “**Board**”) of International Healthway Corporation Limited (the “**Company**”) refers to the article published by Reuters dated 19 December 2016 titled “*Singapore bond market faces S\$22bn refinancing bill*” and another article published by Lianhe Zaobao on 20 December 2016 titled “今年新元债券发行总额跌18.5%” (collectively, the “**Articles**”).

It was stated in both Articles that there is a potential plan for the Company to “extend for two years IHC’s two outstanding bonds”. The “outstanding bonds” mentioned refers to the Medium Term Notes Series 002 of S\$50 million at 7 per cent maturing on 27 April 2017 (the “**MTN Series 002**”), and the Medium Term Notes Series 001 of S\$50 million at 6 per cent maturing on 6 February 2018 (collectively the “**MTNs**”).

The Company wishes to clarify the following:

1. Currently, the Company is working on various funding sources to meet its obligations with respect to the MTN Series 002 maturing in April 2017 (“**Funding Sources**”). There is no firm plan to extend the maturity date for both the MTNs.
2. The Funding Sources include the Company’s proposed refinancing package (the “**Proposed Japan Refinancing**”) of up to JPY 18 billion (approximately S\$223.2 million) as well as the net sales proceeds from the sale of the St Kilda properties (the “**Sale of St Kilda Properties**”). Details of the Proposed Japan Refinancing and the Sale of St Kilda Properties can be found in the Company’s SGXNET announcements dated 15 December 2016 and 24 November 2016, respectively.
3. The Company will continue to divest its non-core assets over the next few months which is expected to meet the Group’s debt obligations as and when they fall due.

Shareholders and other investors are advised to exercise caution when trading in shares of the Company. When in doubt as to the action they should take, shareholders are advised to consult their financial, tax or other advisors.

By Order of the Board

Lim Beng Choo
Executive Director
21 December 2016

*This announcement has been prepared by International Healthway Corporation Limited (the “**Company**”) and its contents have been reviewed by PrimePartners Corporate Finance Pte. Ltd. (the “**Sponsor**”), for compliance with the Singapore Exchange Securities Trading Limited (the “**SGX-ST**”) Listing Manual Section B: Rules of Catalist. The Sponsor has not verified the contents of this announcement. This announcement has not been examined or approved by the SGX-ST. The Sponsor and the SGX-ST assume no responsibility for the contents of this announcement, including the accuracy, completeness or correctness of any of the information, statements or opinions made or reports contained in this announcement.*

The contact person for the Sponsor is Ms Gillian Goh, Director, Head of Continuing Sponsorship, at 16 Collyer Quay, #10-00 Income at Raffles, Singapore 049318, telephone (65) 6229 8088.